EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.15 per share a year ago. These figures are ...

This paper addresses a valuable research question on the heritability of the brain's response to movie watching, given various parameters such as regional spatial hyperalignment and BOLD frequency ...